Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Psiquiatría | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)
INTERVENTIONAL
Inicio: 11 de jun de 2025
ID: NCT06951698
Completado
Fase 4
ClinicalTrials.gov
A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone
INTERVENTIONAL
Inicio: 1 de oct de 2007
ID: NCT00535132
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
INTERVENTIONAL
Inicio: 26 de sept de 2024
ID: NCT06585787
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients
INTERVENTIONAL
Inicio: 1 de dic de 2011
ID: NCT01467713
Completado
Fase 3
ClinicalTrials.gov
An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
INTERVENTIONAL
Inicio: 1 de ago de 2004
ID: NCT00088465
Completado
Fase 3
ClinicalTrials.gov
Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
INTERVENTIONAL
Inicio: 1 de ene de 2011
ID: NCT01235520
Reclutando
Fase 3
ClinicalTrials.gov
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
INTERVENTIONAL
Inicio: 11 de jul de 2023
ID: NCT05980949
Completado
ClinicalTrials.gov
Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety
INTERVENTIONAL
Inicio: 1 de abr de 2007
ID: NCT00960830
Completado
Fase 1
ClinicalTrials.gov
Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone
INTERVENTIONAL
Inicio: 1 de feb de 2014
ID: NCT02087579
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
INTERVENTIONAL
Inicio: 11 de dic de 2010
ID: NCT01192867
Completado
Fase 4
ClinicalTrials.gov
Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00803400
Completado
Fase 2
ClinicalTrials.gov
A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.
INTERVENTIONAL
Inicio: 15 de dic de 2024
ID: NCT06812221
Completado
Fase 3
ClinicalTrials.gov
An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder
INTERVENTIONAL
Inicio: 1 de dic de 2005
ID: NCT00266747
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder
INTERVENTIONAL
Inicio: 1 de jun de 2012
ID: NCT01575561
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01358357
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
INTERVENTIONAL
Inicio: 8 de oct de 2025
ID: NCT07140913
Completado
ClinicalTrials.gov
Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
OBSERVATIONAL
Inicio: 1 de ago de 2008
ID: NCT01080001
Terminado
Fase 2
ClinicalTrials.gov
A Double-blind, Placebo-controlled, Randomized Dose-ranging Trial to Investigate Efficacy and Safety of Intravenous MIJ821 Infusion in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
INTERVENTIONAL
Inicio: 20 de jul de 2021
ID: NCT04722666
Completado
Fase 3
ClinicalTrials.gov
A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression
INTERVENTIONAL
Inicio: 1 de ago de 2009
ID: NCT00958568
Completado
Fase 4
ClinicalTrials.gov
Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study
INTERVENTIONAL
Inicio: 1 de ene de 2009
ID: NCT01279213
Anterior
1
2
3
4
...
434
Siguiente
Filtros